Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg



Status:Completed
Conditions:Breast Cancer, Cancer, Other Indications
Therapuetic Areas:Oncology, Other
Healthy:No
Age Range:18 - Any
Updated:7/15/2018
Start Date:March 2008
End Date:May 21, 2018

Use our guide to learn which trials are right for you!

A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity

RATIONALE: Image-guided radiation therapy uses high-energy x-rays to kill tumor cells.
Specialized radiation therapy that delivers a lower dose of radiation directly to the tumor
may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase II trial is studying the side effects and how well image-guided radiation
therapy works in treating patients with primary soft tissue sarcoma of the shoulder, arm,
hip, or leg.

OBJECTIVES:

Primary

- To determine the effect of reduced radiation volume using image-guided radiotherapy
(IGRT) on lymphedema ≥ grade 2, subcutaneous fibrosis, and joint stiffness at 2 years in
patients with primary soft tissue sarcoma of the extremity.

Secondary

- To estimate the rates of other grade 3-5 adverse events as measured by Common Toxicity
Criteria for Adverse Effects (CTCAE) v3.0.

- To determine the pattern of first failure, including local failure (in-field, marginal,
and outside-field failure), regional failure, distant failure, and death without disease
progression.

- To estimate the rates of local failure, local-regional failure, distant failure, distant
disease-free survival, disease-free survival, overall survival, and second primary
tumor.

- To estimate the rate of wound complications.

- To correlate the degree of late radiation morbidity (defined as any lymphedema,
subcutaneous fibrosis, or joint stiffness) at 2 years with scores on the clinical
measure, Musculoskeletal Tumor Rating Scale (MSTS).

OUTLINE: This is a multicenter study.

- Neoadjuvant radiotherapy: Patients are assigned to 1 of 2 treatment groups (group 1
closed to accrual as of 01/08/10).

- Group 1 (closed to accrual as of 01/08/10): Patients undergo 3-D conformal
radiotherapy (3D-CRT) or intensity-modulated therapy (IMRT) once daily, 5 days a
week, for 4½-5 weeks. Patients also receive up to 6 courses of neoadjuvant,
adjuvant, concurrent, or interdigitated chemotherapy.

- Group 2: Patients undergo 3D-CRT or IMRT once daily, 5 days a week, for 5 weeks.

- Surgery: At 4-8 weeks after completion of neoadjuvant radiotherapy, patients undergo
surgical resection of the tumor. Patients with positive tumor margins (residual tumor)
undergo intraoperative radiotherapy boost or proceed to adjuvant radiotherapy within 2
weeks after surgery.

- Adjuvant radiotherapy: Patients undergo either external-beam radiotherapy (EBRT) once
daily for 8 fractions or brachytherapy.

After completion of study treatment, patients are followed at least every 3 months for 2
years, every 6 months for 3 years, and then annually thereafter.

DISEASE CHARACTERISTICS:

- Histologically confirmed primary soft tissue sarcoma of the upper extremity (including
shoulder) or lower extremity (including hip)

- Incisional or core biopsy required within the past 8 weeks

- No histopathological diagnosis of any of the following:

- Rhabdomyosarcoma

- Extraosseous primitive neuroectodermal tumor (PNET)

- Soft tissue Ewing sarcoma

- Osteosarcoma

- Kaposi sarcoma

- Angiosarcoma

- Aggressive fibromatosis (desmoid tumor)

- Dermatofibrosarcoma protuberans

- Chondrosarcoma

- Extraskeletal myxoid chondrosarcoma allowed

- Tumor must be surgically resectable, as determined by a surgeon within the past 8
weeks

- Limb-preservation surgery alone would not provide adequate local control, as
determined by the surgeon

- No sarcoma of the hand, foot, head, neck, or intra-abdominal or retroperitoneal region
or body wall

- No sarcoma ≥ 32 cm in any direction

- No lymph node or distant metastases, according to the following within the past 8
weeks:

- History/physical examination, including a detailed description of the location,
size, and stage of the sarcoma

- MRI with contrast of the primary tumor

- The maximum dimension of the primary tumor is measured in MRI images

- CT scan of the chest

- Multiple pulmonary nodules < 8 mm without a histological diagnosis detected
incidentally on a non-screening CT scan may be allowed

- CT scan with contrast of the abdomen and pelvis in patients with intermediate- or
high-grade sarcoma of the upper thigh

- No recurrent tumor after prior potentially curative therapy

PATIENT CHARACTERISTICS:

- Zubrod performance status 0-1

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention allowed)

- Bilirubin ≤ 1.5 mg/dL*

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2 times upper
limit of normal*

- Serum creatinine ≤ 1.6 mg/dL OR creatinine clearance ≥ 55 mL/min*

- Left ventricular ejection fraction (LVEF) ≥ 50% by multiple gated acquisition scan
(MUGA) or echocardiogram*

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other invasive malignancy within the past 3 years, except nonmelanomatous skin
cancer or carcinoma in situ of the breast, oral cavity, or cervix

- No severe, active co-morbidity, including any of the following*:

- Unstable angina and/or congestive heart failure requiring hospitalization within
the past 6 months

- Transmural myocardial infarction within the past 6 months

- Acute bacterial infection or fungal infection requiring intravenous antibiotics

- Acquired Immune Deficiency Syndrome (AIDS) or immunocompromised patients

- HIV testing not required

- No NCI CTCAE v 3.0 grade 3-4 electrolyte abnormalities, including any of the
following*:

- Calcium < 7 mg/dL or > 12.5 mg/dL

- Glucose < 40 mg/dL or > 250 mg/dL

- Magnesium < 0.9 mg/dL or > 3 mg/dL

- Potassium < 3mmol/L or > 6 mmol/L

- Sodium < 130 mmol/L or > 155 mmol/L NOTE: *Applies to group 1 only, which was
closed to accrual as of 01/08/10)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior excisional biopsy in which the majority of the tumor (≥ 50%) is removed

- No prior radiotherapy to the region of the study cancer that would result in overlap
of radiotherapy fields

- No other concurrent investigational agents
We found this trial at
15
sites
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1376 Mowry Road
Gainesville, Florida 32610
(352) 273-8010
University of Florida Shands Cancer Center We are the University of Florida Health Cancer Center
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
500 University Drive
Hershey, Pennsylvania 17033
(717) 531-8521
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center Penn State Milton S....
?
mi
from
Hershey, PA
Click here to add this to my saved trials
One Medical Center Drive
Lebanon, New Hampshire 03756
(603) 653-9000
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center Norris Cotton Cancer Center at DHMC in...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
4117 East Fowler Avenue
Tampa, Florida 33612
(813) 745-4673
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Moffitt Cancer...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Edmonton,
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
8800 W. Doyne Avenue
Milwaukee, Wisconsin 53226
(414) 805-6840
Medical College of Wisconsin Cancer Center Cancer touches everyone in our community, and for many,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
4701 Ogletown-Stanton Road
Newark, Delaware 19713
302-623-4450
CCOP - Christiana Care Health Services Christiana Care's Cancer Research Program is part of a...
?
mi
from
Newark, DE
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Cancer Center The Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Johnsbury, Vermont 05819
?
mi
from
Saint Johnsbury, VT
Click here to add this to my saved trials